The FDA Approves JYNARQUE™ as the First Treatment in the United States for Adult Patients with ADPKD
We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).
JYNARQUE™ slows the growth of cysts and the progression of the disease and has been shown to preserve kidney function. The treatment for ADPKD is an oral pill taken twice a day. It is a long-term use drug – extending the time before a patient needs dialysis or a transplant, though not curing the disease. JYNARQUE™ (brand name JINARC™ in Canada) was developed by Otsuka Pharmaceuticals.
- Read the announcement on the PKD Foundation (USA) website.
- Check out the official press release here.
- American residents with questions about JYNARQUE™ can call the PKD Foundation (USA) at 1-800-PKD-CURE
- Interested in reading about Canadian ADPKD treatment options? Check out our own FAQ section.
Special JYNARQUE™ Webinar